Filing Summary
Entity discrepancy: The supplied filing is AMERI Holdings, Inc.’s Form 10-Q, not an Enveric Biosciences, Inc. filing. Confirm the issuer before relying on this summary.
Business context and reporting period
The unaudited report covers the three months ended March 31, 2016, with comparisons to the first quarter of 2015. AMERI describes itself as a technology consulting and solutions firm, generating revenue primarily from consulting services. Results include the effects of its November 2015 acquisition of Bellsoft, an SAP and enterprise technology consulting company.
Financial results and position
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | $7.01 million | $4.28 million; up 63.7% |
| Gross profit / margin | $3.15 million / 44.8% | $1.12 million / 26.1% |
| Operating income (loss) | $(981,316); (14.0)% of revenue | $1.08 million; 25.1% of revenue |
| Net income (loss) | $(1.16) million; $(0.10) per diluted share | $1.08 million; $0.11 per diluted share |
| Operating cash flow | $(1.57) million | $(331,006) |
| Cash and cash equivalents | $505,173 at March 31 | $1.88 million at December 31, 2015 |
Operating expenses were $4.13 million, including $3.61 million of general and administrative expense and $375,405 of nonrecurring expenditures, primarily restructuring costs and legal fees. Interest expense was $113,746. The filing reports a $2,020 tax provision and $62,890 of foreign currency translation loss.
At March 31, total current assets were $5.75 million and current liabilities were $7.93 million, a working-capital deficit of approximately $2.18 million. Total liabilities were $13.43 million, including $5.0 million of 5% convertible notes, $1.48 million of short-term notes, and acquisition consideration payable. Stockholders’ equity was negative $800,061. Cash declined by $1.37 million during the quarter. Investing activities used $48,672; financing activities provided $241,451, attributed in MD&A to borrowing under the FNCC credit facility.
Material changes and management commentary
- Management attributed the revenue increase to the Bellsoft acquisition. Revenue was generated entirely from North American customers in the quarter.
- Gross margin improved to 44.8% from 26.1%, while operating results swung from profit to loss. Management attributed the deterioration principally to higher SG&A, acquisition-related overhead, and nonrecurring costs.
- Operating cash use increased from the prior-year quarter, and cash fell substantially from year-end. Management attributed the cash decline primarily to working-capital uses, including payment of acquisition consideration.
- The company said quarterly results may fluctuate with IT services demand, sales cycles, project mix and scope, and employee utilization. It provided no numerical revenue or earnings guidance.
Debt, contingencies, risks, and subsequent events
- The company’s $5.0 million 5% unsecured convertible note was originally due May 26, 2017. After quarter-end, Lone Star Value exercised 1,111,111 warrants at $1.80 per share for $2.0 million and agreed to extend the note’s maturity by two years. The amendment also provided for a new five-year warrant to purchase 1.0 million shares at $6.00 and governance rights for Lone Star Value.
- After quarter-end, Dhruwa N. Rai purchased 500,000 unregistered shares at $6.00 per share for $3.0 million. The filing also reports grants to Rai of an option for 500,000 shares at $7.00 and restricted stock units for 500,000 shares, contingent on service.
- Bellsoft acquisition consideration includes contingent earn-outs tied to revenue and EBITDA targets. In Q1, the estimated earn-out increased from $400,000 to $500,000 per year for 2016 and 2017. Management notes that fair-value estimates depend on forecasts and assumptions and could materially affect operating results.
- The company leases offices, with disclosed future minimum rental payments totaling approximately $170,000 for 2016–2018. It reported no legal proceedings and no material changes to previously disclosed risk factors.
- Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2016, and reported no material control changes during the quarter.
Important facts for investors to verify
- Confirm that AMERI Holdings—not Enveric Biosciences—is the intended issuer and that this 2016 filing is the intended reporting period.
- Review the subsequent financing and note amendment, including the extended maturity, warrant terms, board-designation rights, and resulting dilution.
- Assess near-term liquidity given the $505,173 quarter-end cash balance, operating cash burn, working-capital deficit, and acquisition payment obligations; confirm how subsequent proceeds affected liquidity.
- Reconcile acquisition-related liabilities and earn-out estimates, and evaluate whether Bellsoft’s contribution supports the increased revenue and improved gross margin.
- Check the company’s share count and potential dilution from outstanding warrants, options, restricted stock units, and post-quarter issuances.